Mark Cuban

Entrepreneur · Cost Plus Drugs · GoodRx · S.3822

He is not a physician or a senator. He is a billionaire who looked at the drug pricing machine, concluded the intermediary layer was pure extraction, and then built a company to prove it. The proof is in the prices. Everything else followed from that.

Section I

The Stella McMahon Intervention

Denial → Personal Response → Proof of Concept

Stella McMahon had a denial for a medical flight. Her family was public about it. Mark Cuban saw it, reached out directly, and funded the flight. He didn't lobby for a policy change. He wrote a check because the gap was real and visible and he had the means to close it.

That intervention is documented and cited. It is the concrete, personal version of the argument that Cost Plus Drugs makes in the aggregate: the system extracts money that does not belong to it, and the harm is measurable in dollars and outcomes. Cuban's response to Stella was not a political statement — it was a calculation. This is what the gap costs a family. This is what filling it looks like.

The McMahon intervention is cited by multiple voices on this site as evidence that the accountability argument has moved from rhetoric to action — that reform-aligned individuals are now operating in the space that the system has vacated.

Section II

Cost Plus Drugs

Transparent Pricing as Structural Argument

Cost Plus Drugs publishes the cost of every medication it sells: manufacturer price, plus a fixed markup for operations, plus a dispensing fee. That is the price. No PBMPBM — Pharmacy Benefit ManagerA Pharmacy Benefit Manager (PBM) is the intermediary that administers prescription-drug benefits for health plans and employers — deciding which drugs a plan covers, negotiating re… spread. No opaque rebate structure. No insurer-negotiated list price that bears no relationship to what anyone actually pays.

The model works because the drugs cost what they cost to manufacture, and the traditional pricing chain between manufacturer and patient is extractive at every layer. Cost Plus removed the extraction layers and passed the margin to patients. The result: medications that routinely cost hundreds of dollars through insurance channels cost single-digit or low double-digit dollars through Cost Plus.

The Model

Cost + Markup

No PBM. No spread. No mystery.

The Proof

Published Prices

Every medication, every margin, public.

The Argument

The Gap Is Extraction

What you paid before was not cost.

This is not a discount program. It is a structural argument made with prices. Every medication listed on the Cost Plus site is a data point in the accountability case: the spread between what you were paying and what the drug costs is money that was taken from you by intermediaries who added no medical value.

Section III

GoodRx and the Markup Proof

When Bypassing Insurance Is Cheaper, the Model Is Exposed

GoodRx is not a drug company. It is a price negotiator — it aggregates pharmacy relationships and passes negotiated prices to consumers in the form of a discount card. Its existence should not be necessary. The prices it surfaces are almost always lower than going through insurance, because the insurance markup layer is not adding value — it is adding cost.

Cuban has spoken directly about the GoodRx proof: if bypassing your insurance and paying cash through a discount card is cheaper than using coverage you're paying premiums for, the insurance layer is extractive. This is not a fringe argument. It is an arithmetic observation. The math is available at any pharmacy counter.

The Trump Plan Observation

The pricing structure of Trump's proposed drug pricing plan was consistently a few dollars higher than the equivalent GoodRx price for the same medications — close enough to raise a serious question about the underlying mechanism. The argument: if the plan is effectively drop-shipping GoodRx product at a slight premium, the administration has validated the GoodRx model while adding a margin for someone else. Bipartisan acknowledgment of the GoodRx baseline is itself significant evidence that the insurance markup argument has crossed ideological lines.

GoodRx has bipartisan political support precisely because price transparency produces legible evidence. When Republicans and Democrats can both see the markup, the markup can't be defended as a feature. It becomes a visible extraction. Cuban understood this earlier than most legislators.

Section IV

The Malpractice Question

The Accountability Gap That Led to the Clinical Integrity Amendment

Cuban posed the question publicly: when an insurer denies necessary care and the patient is harmed as a direct result — is that malpractice? Physicians are liable for clinical decisions. Insurers deny clinical care with no equivalent liability structure. The decision to deny a surgery, a drug, a diagnostic procedure — these are clinical decisions. They are made by entities that carry no clinical liability.

DocSchmidt's clip featuring this question got 77,000 likes. The question didn't go viral because it was provocative — it went viral because it names a structural gap that physicians and patients both recognize as real. The liability asymmetry is the accountability problem. Physicians are sued for bad outcomes. Insurers profit from them.

Connection to the Clinical Integrity Amendment

The Clinical Integrity Amendment to S.3822 — championed by former Rep. Brad Wenstrup (R-OH) — addresses this gap directly. It was not drafted in a vacuum. The malpractice question that Cuban and DocSchmidt surfaced is the legislative problem that amendment was designed to solve. The accountability language in the bill traces back, at least in part, to this public conversation.

Cuban's framing of this issue is cited by Brad Wenstrup in The Hill, Rep. Greg Murphy in a congressional hearing, and DocSchmidt's viral clip. The question moved from Twitter to Congress.

Section V

S.3822 — "A No Brainer"

The Break Up Big Medicine Act — Warren & Hawley · Feb. 10, 2026

When Sens. Elizabeth Warren (D-MA) and Josh Hawley (R-MO) introduced the Break Up Big Medicine Act (S.3822) on February 10, 2026 — to force the structural separation of insurers, PBMs, and the providers they own — Cuban endorsed it publicly and without hedging, quote-posting the bill's announcement. The Act attacks vertical integration at the root: it would require a conglomerate that owns an insurer, a PBM, and a physician network to divest, so no single parent profits at every point of the same transaction.

"Great job @HawleyMO & @SenWarren — LOVE THIS. Anyone in Congress that doesn't support this, doesn't want lower cost healthcare for Americans. This is a no brainer. Let's hope @POTUS puts his weight behind this."

— Mark Cuban (@mcuban), X · February 10, 2026 — quote-posting the Break Up Big Medicine Act announcement

Cuban's endorsement is significant not because a celebrity backed a bill, but because the endorsement carried the credibility of someone who had already built a working alternative to opacity in drug pricing. Cost Plus Drugs is proof that transparency is operationally viable. His endorsement of the break-up bill is consistent with the same structural diagnosis: when one parent owns the insurer, the PBM, and the provider, the intermediary captures the value, not the patient.

Why the Endorsement Matters

It comes from someone who already proved the opposite model works. Cost Plus Drugs is transparent pricing at scale. The S.3822 endorsement extends that argument from pricing to structure: breaking up the conglomerates removes the same extractive middle layer his transparent pricing routes around.

The Bipartisan Signal

S.3822 has Republican and Democratic co-sponsors. Cuban's backing crossed the same lines. The break-up-Big-Medicine argument — like the pricing transparency argument — is not ideological. It is structural. The math is visible from both sides.